<DOC>
	<DOCNO>NCT02001272</DOCNO>
	<brief_summary>The current standard first-line chemotherapy advance ovarian cancer combination carboplatin AUC 5mg/mL/min paclitaxel 175 mg.m-² . This combination feasible select elderly patient include prospective trial . These trial , however , include minority elderly population . In wide selection patient &gt; 70 year old , standard carboplatin-paclitaxel regimen show induce excess toxicity premature treatment stopping . For elderly patient think vulnerable high risk toxicity standard 3-weekly carboplatin-paclitaxel regimen , option use routine practice . One option delete paclitaxel treat elderly patient carboplatin single agent . An alternative use carboplatin-paclitaxel regimen weekly schedule drug report MITO ( Multicentre Italian Trial Ovarian Cancer ) . To date , randomize trial could give u evidence select patient could benefit one regimen describe . The 4th Ovarian Cancer Consensus Conference indeed recognise medical unmet need adapt therapy elderly patient ovarian cancer necessity additional research population . Recently , GINECO describe Geriatric Vulnerability Score ( GVS ) population elderly patient advance ovarian cancer include specific multicenter phase II trial . The best proportional hazard model fit overall survival identify follow geriatric covariates score poor survival risk factor : ADL score &lt; 6 , IADL score &lt; 25 , HADS score &gt; 14 , albuminemia &lt; 35g/L , lymphopenia &lt; 1G/L . GVS sum risk factor patient . Using cut 3 , GVS identify group patient high risk severe toxicity , early cessation treatment , unplanned hospitalization adverse outcomes . This international multicentre randomize phase II trial compare success rate deliver 6 course chemotherapy evidence efficacy without premature termination progression , death unacceptable toxicity three different chemotherapy regimen select population elderly patient GVS ≥ 3 : - Arm A : Paclitaxel 175mg/m²/3 hour , I.V . carboplatin AUC 5 , I.V . every 3 week - Arm B : Carboplatin monotherapy AUC 5 6 every 3 week - Arm C : Weekly paclitaxel 60 mg/m²/1 hour weekly carboplatin AUC 2 ( d1 , d8 , d15 every 4 week ) The total number patient enrol 240 , ie 22 arm ( total = 66 ) first step , 58 arm ( total=174 ) interim analysis .</brief_summary>
	<brief_title>EWOC-1 Trial : Carboplatin +/- Paclitaxel Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Woman &gt; 70 year old Histologically cytologically proven FIGO stage III IV epithelial ovarian cancer peritoneal primary fallopian tube . A cytological proof accept associate ratio CA125/CEA &gt; 25 radiological pelvic mass . GVS ( Geriatric Vulnerability Score ) &gt; 3 . Adequate bone marrow function include follow : Neutrophils ≥ 1.5 x 109/L , platelet ≥100 x 109/L hemoglobin ≥9 g/dL . Adequate glomerular filtration rate &gt; 40 ml/min ( estimate base MDRD Chatelut formula sufficient ) No icterus . Life expectancy &gt; 3 month . Written inform consent obtain . Covered Health System applicable Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Prior history chemotherapy . Prior history radiotherapy may affect patient tolerability chemotherapy . Major perturbation liver biology : Bilirubin &gt; 2 fold upper normal limit ( UNL ) , SGOTSGPT &gt; 3 fold UNL . Patient unable regularly follow reason ( geographic , familial , social , psychologic ) . Any mental physical handicap risk interfere appropriate treatment . Known allergy Cremophor ® EL contain drug . Any administrative legal supervision applicable</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Elderly</keyword>
	<keyword>Vulnerable</keyword>
	<keyword>Ovarian cancer</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>